A randomized, double-blind, placebo-controlled clinical trial in 24 patients of both sexes aged between 30 and 60 years, with a diagnosis of metabolic syndrome according to the modified IDF criteria, without treatment.
They will be assigned randomly two groups of 12 patients, each to receive 150 mg